Research Funding

  • July 16, 2018 - June 30, 2023 - Defining and targeting ER quality control dependence in rhabdomyosarcoma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: K08CA218691
  • July 16, 2018 - June 30, 2023 - Defining and targeting ER quality control dependence in rhabdomyosarcoma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: K08CA218691
  • July 16, 2018 - June 30, 2023 - Defining and targeting ER quality control dependence in rhabdomyosarcoma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: K08CA218691
  • July 16, 2018 - June 30, 2023 - Defining and targeting ER quality control dependence in rhabdomyosarcoma, Principal Investigator. Sponsor: NIH, Sponsor Award ID: K08CA218691

Education

Stanford University, Stanford CA, BS, 06/2003, Biological Sciences
Stanford University, Stanford CA, MS, 06/2003, Biological Sciences
Univ. of California San Francisco, MD, 05/2008, Medicine
Univ. of California San Francisco, Resident, 06/2011, Pediatrics
Univ. of California San Francisco, Fellow, 06/2014, Pediatric Hematology-Oncology

Honors & Awards

  • 2007
    American Society of Hematology Travel/Merit Award
  • 2007-2008
    UCSF Certificate of Graduate Curriculum in Biomedical Research
  • 2008
    Inducted into Alpha Omega Alpha Honor Society
  • 2009
    UCSF Pediatrics Resident Teaching Award
  • 2011
    Lucy S. Crain Award for providing exceptional primary care to patients with special needs
  • 2012
    Accepted into AACR “Molecular Biology in Clinical Oncology” workshop
  • 2013
    Campini Foundation Fellowship in Pediatric Oncology Research
  • 2017
    2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research
  • 2017
    Caroline Casey Award for Dignity and Worth of Persons

Selected Publications

  1. Rees HD, Hills NK, Sabnis AJ, Tulpule AB, Shimotake TK, Goldsby RE. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016. Cancer Rep (Hoboken). 2021 Jul 13; e1503.  View on PubMed
  2. Alanna J. Church, Laura Corson, Pei-Chi Kao, Alma Imamovic-Tuco, Wenjun Kang, Navin R. Pinto, Luke Maese, Theodore Willis Laetsch, AeRang Kim, Susan Colace, Margaret E Macy, Mark A. Applebaum, Rochelle Bagatell, Amit J. Sabnis, Daniel Weiser, Julia Lynne Glade Bender, Samuel Louis Volchenboum, Steven G. DuBois, Wendy B. London, Katherine A. Janeway. Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10005-10005.  View on PubMed
  3. Giles Robinson, Ami Desai, Ellen Basu, Jennifer Foster, Karen Gauvain, Amit Sabnis, Suzanne Shusterman, Margaret Macy, Luke Mease, Janet Yoon, Thomas Cash, Mohamed Abdelbaki, Kellie Nazemi, Christine Pratilas, Brian Weiss, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Amar Gajjar. HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS. Neuro-Oncology. 2020 Dec 4; 22(Suppl 3):iii344-iii344.  View on PubMed
  4. Katherine Tarlock, Soheil Meshinchi, Jeffrey E. Rubnitz, Seth E. Karol, Barbara Spitzer, Amit J. Sabnis, Asif Pathan, Boo Messahel. Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood. 2020 Nov 5; 136(Supplement 1):23-24.  View on PubMed
  5. J. Chew, S.A. Lloyd, R.A. Okimoto, A. Sabnis, E. Nakakura, C. Corvera, M.N. Zimel, A.E. Horvai, S.J. Cho, R.L. Wustrack, A.R. Gottschalk, R.J. O'Donnell, T.M. Jahan, S.E. Braunstein. Outcomes of Elderly Patients with Soft Tissue Sarcoma of the Extremities. International Journal of Radiation Oncology • Biology • Physics. 2020 Nov 1; 108(3):e6.  View on PubMed
  6. Lavergne V, Sabnis A, Tupule A, Davidson PR, Kline C, Matthay K, Nicolaides T, Goldsby R, Braunstein S, Fogh SE, Sneed PK, Menzel P, Nakamura A, DuBois SG, Haas-Kogan DA, Nakamura JL. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654.  View on PubMed
  7. Ami Vijay Desai, Giles W. Robinson, Ellen M. Basu, Jennifer Foster, Karen Gauvain, Amit Sabnis, Suzanne Shusterman, Margaret E Macy, Luke Maese, Janet Yoon, Thomas Cash, Mohamed Abdelbaki, Kellie Nazemi, Brian D. Weiss, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Amar J. Gajjar, Elizabeth Fox. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):107-107.  View on PubMed
  8. Giles Robinson, Ami Desai, Karen Gauvain, Ellen Basu, Kathleen Dorris, Luke Maese, Amit Sabnis, Jennifer Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Amar Gajjar. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi186-vi186.  View on PubMed
  9. Heunis JC, Cheah JW, Sabnis AJ, Wustrack RL. Use of three-dimensional printing and intraoperative navigation in the surgical resection of metastatic acetabular osteosarcoma. BMJ Case Rep. 2019 Sep 30; 12(9).  View on PubMed
  10. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 08 27; 28(9):2317-2330.e8.  View on PubMed
  11. Giles W. Robinson, Amar J. Gajjar, Karen Marie Gauvain, Ellen M. Basu, Margaret E Macy, Luke Devon Maese, Amit J. Sabnis, Jennifer Haunani Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Ami Vijay Desai. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):10009-10009.  View on PubMed
  12. Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019 03; 25(3):185-197.  View on PubMed
  13. Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci. 2018 09 05; 131(17).  View on PubMed
  14. Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10536-10536.  View on PubMed
  15. Cohen JN, Sabnis AJ, Krings G, Cho SJ, Horvai AE, Davis JL. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. Hum Pathol. 2018 11; 81:281-290.  View on PubMed
  16. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC, Auerbach AD. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infect Control Hosp Epidemiol. 2017 09; 38(9):1039-1047.  View on PubMed
  17. Sabnis AJ, Bivona TG. HSP70 dependence in rhabdomyosarcoma: Seed or soil? . 2017 01 17; 16(2):147-148.  View on PubMed
  18. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20.  View on PubMed
  19. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.  View on PubMed
  20. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.  View on PubMed

Go to UCSF Profiles, powered by CTSI